Regeneron Pharmaceuticals, Inc.
REGN
$957.00
$19.392.07%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 12.58B | 12.65B | 12.27B | 11.98B | 11.81B |
| Total Other Revenue | 536.10M | 451.30M | 397.20M | 387.10M | 365.10M |
| Total Revenue | 13.12B | 13.10B | 12.67B | 12.37B | 12.17B |
| Cost of Revenue | 6.25B | 6.14B | 5.86B | 5.46B | 5.15B |
| Gross Profit | 6.86B | 6.95B | 6.81B | 6.91B | 7.02B |
| SG&A Expenses | 2.63B | 2.55B | 2.44B | 2.27B | 2.12B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -2.10M | -8.20M | -53.40M | -70.20M | -89.90M |
| Total Operating Expenses | 8.88B | 8.69B | 8.25B | 7.66B | 7.18B |
| Operating Income | 4.23B | 4.41B | 4.42B | 4.71B | 4.99B |
| Income Before Tax | 4.20B | 4.38B | 4.78B | 4.66B | 4.86B |
| Income Tax Expenses | 245.70M | 385.30M | 476.40M | 473.00M | 520.40M |
| Earnings from Continuing Operations | 3.95K | 3.99K | 4.30K | 4.18K | 4.34K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 3.95B | 3.99B | 4.30B | 4.18B | 4.34B |
| EBIT | 4.23B | 4.41B | 4.42B | 4.71B | 4.99B |
| EBITDA | 4.65B | 4.82B | 4.82B | 5.08B | 5.34B |
| EPS Basic | 37.05 | 37.36 | 40.18 | 39.03 | 40.51 |
| Normalized Basic EPS | 27.24 | 28.12 | 27.58 | 28.75 | 30.06 |
| EPS Diluted | 34.75 | 35.05 | 37.82 | 36.79 | 38.23 |
| Normalized Diluted EPS | 25.56 | 26.40 | 25.97 | 27.11 | 28.38 |
| Average Basic Shares Outstanding | 427.00M | 427.40M | 428.00M | 428.90M | 428.60M |
| Average Diluted Shares Outstanding | 455.10M | 455.30M | 454.70M | 454.80M | 453.90M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
